[ad_1]
By Anthony O. Goriainoff
AstraZeneca said Thursday that its and MSD’s Lynparza cancer treatment had been approved in the U.S. for the treatment of metastatic castration-resistant prostate cancer, or mCRPC.
The Anglo-Swedish pharma giant said Lynparza, in combination with abiraterone and prednisone, reduced the risk of disease progression or…
[ad_2]
[ad_1] IE 11 is not supported. For an optimal experience visit our site on another browser. Now Playing…
[ad_1] PLYMOUTH, Mass. — PLYMOUTH, Mass. (AP) — Lindsay Clancy searched online about hallucinations, psychosis and the side…
[ad_1] U.S. Immigration and Customs Enforcement officers may soon be outfitted with gloves that can deliver painful electric…
[ad_1] NEWYou can now listen to Fox News articles! Good morning and welcome to Fox News’ morning newsletter,…